Advantages of preoperative localization and surgical resection of metastatic axillary lymph nodes using magnetic seeds after neoadjuvant chemotherapy in breast cancer


Por: Martinez, AM, Rosell, IV, Gomez, AS, Catanese, A, Molina, MP, Suarez, MS, Miguel, IP, Aulina, LB, Gozalvez, CR, Ibanez, JFJ, Martinez, PR, Roman, SM, Vila, MM and Tomas, MAL

Publicada: 1 mar 2021 Ahead of Print: 23 nov 2020
Resumen:
Purpose: To assess the safety and effectiveness of magnetic seeds in preoperative localization and surgical dissection of metastatic axillary lymph nodes (LN+) in breast cancer patients with axillary involvement, after neoadjuvant chemotherapy (NAC). In addition, to assess the impact of targeted axillary dissection (TAD) in reducing the rate of false negatives (FN) in sentinel lymph node biopsy (SLNB). Materials and Methods: A cross-sectional prospective cohort study was conducted from April 2017 to September 2019, including breast cancer patients with axillary lymph node involvement treated with NAC. Prior to NAC, the LN+ were marked by ultrasound-guided clip insertion. After NAC, a magnetic seed (Magseed (R)) was inserted in the clip-marked lymph node (MLN). During surgery, the MLN was located and removed with the aid of a magnetic detection probe (Sentimag (R)) and the sentinel lymph node was removed. Axillary lymph node dissection (ALND) was used to determine the rate of FN for SLNB alone and the combination of SLNB and MLN dissection, called TAD. Results: The study included 29 patients (mean age, 55; range, 30-78 years). Selective preoperative localization and surgical dissection were successful for all 30 MLNs (100%). The MLN corresponded to the SLN in 50% of cases. After ALND, there were 21.4% (3/14) FN with SLNB alone and 5.9% (1/17) with TAD. Conclusions: Following NAC, selective surgical removal of MLN by preoperative localization using magnetic seeds is a safe and effective procedure with a success rate of 100%. Adding TAD reduces the rate of FN associated with SLNB alone.

Filiaciones:
Martinez, AM:
 Hosp Univ Germans Trias & Pujol HUGTiP, Breast Diagnost Imaging Unit BDIU, Dept Radiol, Barcelona, Spain

Rosell, IV:
 Hosp Clin Barcelona, Dept Gynecol, Barcelona, Spain

Gomez, AS:
 Hosp Univ Germans Trias & Pujol HUGTiP, Breast Diagnost Imaging Unit BDIU, Dept Radiol, Barcelona, Spain

Catanese, A:
 Hosp Univ Germans Trias & Pujol HUGTiP, Breast Diagnost Imaging Unit BDIU, Dept Radiol, Barcelona, Spain

Molina, MP:
 Hosp Univ Germans Trias & Pujol HUGTiP, Breast Diagnost Imaging Unit BDIU, Dept Radiol, Barcelona, Spain

:
 HUGTIP, Dept Nucl Med, Barcelona, Spain

:
 HUGTIP, Dept Gen Surg, Barcelona, Spain

:
 HUGTIP, Dept Gen Surg, Barcelona, Spain

Gozalvez, CR:
 HUGTiP, Dept Gynecol, Barcelona, Spain

:
 HUGTIP, Dept Gen Surg, Barcelona, Spain

Martinez, PR:
 HUGTIP, Dept Pathol, Barcelona, Spain

Roman, SM:
 HUGTiP, Dept Gynecol, Barcelona, Spain

:
 ICO, Dept Oncol, Barcelona, Spain

Tomas, MAL:
 HUGTiP, Dept Gynecol, Barcelona, Spain
ISSN: 09607404





SURGICAL ONCOLOGY-OXFORD
Editorial
Elsevier BV, THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND, Países Bajos
Tipo de documento: Article
Volumen: 36 Número:
Páginas: 28-33
WOS Id: 000612081300005
ID de PubMed: 33285433

MÉTRICAS